https://pharminent.com/oncology/oncology-intelligence-digest-june-5-2026/ 2026-06-06T17:22:30Z Pharminent en Oncology Intelligence Digest • June 5, 2026 2026-06-06T17:22:27Z Blog https://pharminent.com/market-access/market-access-intelligence-weekly-digest-june-5-2026/ 2026-06-05T19:25:46Z Pharminent en MARKET ACCESS INTELLIGENCE • Weekly Digest • June 5, 2026 2026-06-05T19:25:42Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-june-5-2026/ 2026-06-05T18:51:11Z Pharminent en Strategic News Watch • June 5, 2026 2026-06-05T18:46:10Z Blog https://pharminent.com/lilly-and-novo-face-off-at-ada-2026-as-others-seek-to-compete-in-obesity/ 2026-06-05T16:23:46Z Pharminent en Lilly and Novo face off at ADA 2026 as others seek to compete in obesity 2026-06-05T13:36:00Z Blog https://pharminent.com/the-next-fda-commissioner-must-be-a-champion-for-gene-therapies/ 2026-06-05T16:23:55Z Pharminent en The next FDA commissioner must be a champion for gene therapies 2026-06-05T13:00:00Z Blog https://pharminent.com/medicare-advantage-in-2026-enrollment-update-and-key-trends/ 2026-06-05T16:23:52Z Pharminent en Medicare Advantage in 2026: Enrollment Update and Key Trends 2026-06-05T13:00:00Z Blog https://pharminent.com/medicare-advantage-in-2026-premiums-out-of-pocket-limits-supplemental-benefits-and-prior-authorization/ 2026-06-07T22:16:10Z Pharminent en Medicare Advantage in 2026: Premiums, Out-of-Pocket Limits, Supplemental Benefits, and Prior Authorization 2026-06-05T13:00:00Z Blog https://pharminent.com/otsuka-energizes-iga-neuropathy-space-with-new-phase-3-voyxact-data/ 2026-06-05T16:23:58Z Pharminent en Otsuka energizes IgA neuropathy space with new Phase 3 Voyxact data 2026-06-05T12:00:44Z Blog https://pharminent.com/stakeholders-want-makarys-voucher-program-paused-call-for-fda-independence/ 2026-06-05T16:24:02Z Pharminent en Stakeholders want Makary's voucher program paused, call for FDA independence 2026-06-05T11:25:30Z Blog https://pharminent.com/pharma-is-betting-big-on-pd-1-vegf-bispecifics-but-are-companies-chasing-the-wrong-target/ 2026-06-05T16:24:03Z Pharminent en Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target? 2026-06-05T11:00:00Z Blog https://pharminent.com/biogens-salanersen-gains-fda-breakthrough-therapy-designation-for-sma/ 2026-06-05T16:24:06Z Pharminent en Biogen's salanersen gains FDA breakthrough therapy designation for SMA 2026-06-05T09:21:56Z Blog https://pharminent.com/pfizer-signs-licence-agreement-with-chai-for-ai-drug-discovery-2/ 2026-06-05T16:24:09Z Pharminent en Pfizer signs licence agreement with Chai for AI drug discovery 2026-06-05T09:17:54Z Blog